Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neohesperidin dihydrochalcone (NHDC) is a semi-synthetic flavonoid sweetener derived from citrus fruits, primarily known for its intense sweetness and use as a food additive (E959). Beyond its application in the food industry, NHDC has emerged as a potential therapeutic agent due to its antioxidant and anti-inflammatory properties. Recent research, such as that presented at AACR 2026, identifies NHDC as a potent inhibitor of ferroptosis, a form of iron-dependent regulated cell death. It acts by targeting the System Xc− pathway, mitigating the accumulation of lipid reactive oxygen species (ROS) and modulating the expression of ferroptosis-related proteins like SLC7A11 and SLC3A2. This mechanism suggests potential applications in treating various ferroptosis-related pathologies, including cancer and neurodegenerative diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neohesperidin dihydrochalcone.